Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy.
CTG, cytosine-thymineguanine
CUG, cytosine-uracil-guanine
DM1, type 1 myotonic dystrophy
INR, international normalized ratio
LVEF, left ventricular ejection fraction
NT-proBNP, N-terminal pro B-type natriuretic peptide
NYHA, New York Heart Association
RNA, ribonucleic acid
SVC, superior vena cava
TRPV-2, transient receptor potential vanilloid-2 subtype
cardiogenic shock
cardiomyopathy
heart failure
inotropes
myotonic dystrophy
probenecid
Journal
JACC. Case reports
ISSN: 2666-0849
Titre abrégé: JACC Case Rep
Pays: Netherlands
ID NLM: 101757292
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
12
04
2019
revised:
27
06
2019
accepted:
07
07
2019
entrez:
28
7
2021
pubmed:
21
8
2019
medline:
21
8
2019
Statut:
epublish
Résumé
A 56-year-old man with multiple cardiac manifestations of type 1 myotonic dystrophy, including severe, nonischemic cardiomyopathy, presented in refractory cardiogenic shock requiring inotropic therapy. Given his wishes to die without having any intravenous medications, he was started on oral probenecid therapy, which allowed for successful elimination of his intravenous therapies. (
Identifiants
pubmed: 34316787
doi: 10.1016/j.jaccas.2019.07.008
pii: S2666-0849(19)30136-6
pmc: PMC8301499
doi:
Types de publication
Case Reports
Langues
eng
Pagination
213-217Informations de copyright
© 2019 The Authors.
Références
J Mol Cell Cardiol. 2012 Jul;53(1):134-44
pubmed: 22561103
J Am Heart Assoc. 2018 Jan 13;7(2):
pubmed: 29331959
Cardiovasc Res. 1997 Jan;33(1):13-22
pubmed: 9059523
Anesthesiology. 1972 May;36(5):472-8
pubmed: 4553795
J Am Coll Cardiol. 2018 Mar 6;71(9):994-1004
pubmed: 29496000
J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):358-67
pubmed: 20176601
Am Heart J. 2004 Feb;147(2):224-7
pubmed: 14760317
Neuromuscul Disord. 2009 Jul;19(7):468-72
pubmed: 19481939